Moderators: Larry A. Allen
                   Akshay S. Desai

10:30 AM
Introduction: The "Typical" Patient
Akshay S. Desai

10:35 AM
History and Clinical Assessment
Mark H. Drazner

10:45 AM
Family History and Evolving Role of Genetic Testing
Neal Lakdawala

10:55 AM
Imaging and Invasive Assessment of New-Heart Failure
James E. Udelson

11:05 AM
Questions

11:15 AM
Initial Medical Therapy: Selection, Initiation, and Titration of ACE-Inhibitors, Angiotensin Receptor Antagonists and Beta-Blockers
Michelle M. Kittleson

11:30 AM
The 'Third Drug': Aldosterone Antagonist, Isordil/Hydralazine, or ARB?
William G. Cotts

11:40 AM
Other Medical Therapy: Diuretics, Digoxin, Supplements
Denise D. Barnard

11:50 AM
Questions and Answers
Faculty

12:00 PM
Risk Assessment: Assessment of Functional Capacity and Role for Cardiac Biomarkers
TBN

12:10 PM
HF-PEF: Workup, Pathophysiology and Management
Prakash C. Deedwania

12:25 PM
Acute Decompensated Heart Failure: Practical Considerations and Approach to Management
Steven R. Goldsmith

12:40 PM
Questions and Answers
Faculty

Learning Objective: Describe methods for evaluating and managing chronic and acute HF, including standard drug therapy.

Chair: Mandeep R. Mehra

1:00 PM
Welcome and Introduction
Mandeep R. Mehra

1:05 PM
The Orphan Right and the Abundant Left
Milton Packer

1:25 PM
Questions and Answers with Audience Response

1:30 PM
Evaluating the Right Ventricle: Opening the Oyster
Paul Forfia

1:50 PM
Questions and Answers with Audience Response

2:00 PM
Right Ventricular Malfeasance in PAH: Righting A Wrong
Vallerie Mclaughlin

2:20 PM
Questions and Answers with Audience Response

2:30 PM
Repaired Congenital Heart Defect: Not Free and Clear
Curt Daniels

2:50 PM
Questions and Answers with Audience Response

Learning Objectives:

1. Describe the unique pathology of right ventricle (RV) failure and differentiate it from Left Ventricular Failure
2. Use appropriate hemodynamic assessment in the identification of RV failure
3. Describe effective strategies for managing pulmonary arterial hypertension (PAH)
4. Evaluate and manage adult patients with repaired congenital heart defects

Supported by an educational grant from Acetlion Pharmaceuticals

Although this program is not part of the scientific program as planned by the HFSA Program Committee, it has been reviewed and approved by the HFSA Satellite Program Committee.

Chairs: Joseph G. Rogers
           Randall C. Starling

2:00 PM
Introduction and Overview
Joseph G. Rogers

2:05 PM
Who Should Receive Mechanically Assisted Circulation in 2012: Lessons Learned from INTERMACS and MEDAMACS?
Lynne W. Stevenson

2:17 PM
Short-Term Device Strategies for Acute Cardiac Failure: What to Do When Medications Fail?
Mark Slaughter

2:29 PM
Contemporary Results with Durable Mechanical Circulatory Support
J. Eduardo Rame

2:41 PM
Bi-Ventricular Heart Failure: Assessing the Right Ventricle and Available Treatment Options
Francisco Arabia

2:53 PM
Question & Answer and Panel Discussion
Moderator: Randall C. Starling

Learning Objectives:

1. Identify appropriate candidates for mechanically assisted circulation
2. Outline short-term device strategies for acute heart failure when medications are not sufficient
3. Describe current results with durable mechanical circulatory support
4. Assess the right ventricle and identify available treatment options

Supported by an educational grant from Thoratec, HeartWare, SynCardia

Although this program is not part of the scientific program as planned by the HFSA Program Committee, it has been reviewed and approved by the HFSA Satellite Program Committee.

Moderators: Steven R. Houser
                   Jeffrey D. Molkentin

3:30 PM^*
Strategies to Repair the Failing Heart
The 6^th Distinguished Lecture in Basic Science
Eric N. Olson

(Award to be presented immediately following lecture)

4:30 PM^*
Cardiac-Derived Stem Cells to Rebuild the Failing Heart
Eduardo Marban

5:00 PM^*
Embryonic Stem Cells to Rebuild the Failing Heart
Charles E. Murry

5:30 PM^*
Induced Pluripotent Stem Cells for Cardiac Repair
Andre Terzic

^* Includes 5 minute audience discussion

Learning Objective: Describe emerging strategies using stem cells or fibroblasts to repair the failing heart.

Chair: John Teerlink

4:00 PM
Welcome and Introduction
John Teerlink

4:10 PM^*
Hypervolemic Hyponatremia in Patients with Heart Failure: Pathogenesis and Treatment Options
Joseph Verbalis

4:40 PM^*
Lessons from Clinical Trials of Vasopressin Receptor Antagonists in Heart Failure
Marvin A. Konstam

5:05 PM^*
Current Guidelines and Treatment Options for Improving Outcomes in the Heart Failure Patient with Hyponatremia (Case #1)
Paul Hauptman

5:35 PM
Caring for Heart Failure Patients with Hyponatremia: A Nursing Perspective (Case #2)
Linda J. Ordway

5:50 PM
Discussion with Faculty
John Teerlink

^* Includes 10 minute question-and-answer

Learning Objectives:

1. Review the role of arginine vasopressin in the pathogenesis of hypervolemic hyponatremia in patients with heart failure
2. Assess the safety and efficacy of current and emerging therapies for the management of hyponatremia in patients with heart failure
3. Discuss evidence-based guidelines and strategies on the management of  hyponatremia in acute decompensated heart failure

Supported by an educational grant from Otsuka America Pharmaceuticals

Although this program is not part of the scientific program as planned by the HFSA Program Committee, it has been reviewed and approved by the HFSA Satellite Program Committee.

Chair: Leslie A. Saxon

4:00 PM
Introduction and Overview
Leslie A. Saxon

4:05 PM^*
The Incidence and Management of Inappropriate Shocks in Patients with Heart Failure
Michael Gold

4:30 PM^*
The Role of ICDs With and Without Leads in the Management of Patients with Heart Failure
Martin C. Burke

4:55 PM^*
A New Look at Device Diagnostics: What Should We Be Measuring?
John P. Boehmer

5:15 PM^*
Could an ICD with Monitoring Features Prevent Right Heart Failure?
Lynne W. Stevenson

5:35 PM
Patient Management Case 1: Pre-Syncope post CR
Moderator: Leslie A. Saxon
Faculty

5:45 PM
Patient Management Case 2: AV Node Ablation for Atrial Fibrillation in HF with Preserved Ejection Fraction – Which Device?
Moderator: Leslie A. Saxon
Faculty

5:55 PM
Final Comments and Discussion
Faculty

^* Includes 5 minute question-and-answer

Learning Objectives:

1. Manage and avoid complications with inappropriate ICD shocks
2. Explain the rationale for the use of subcutaneous ICD devices in suitable patients with severe heart failure
3. Identify the benefits and pitfalls of remote physiologic monitoring with implantable devices
4. Outline a strategy for the use of remote monitoring in patients with heart failure
5. Choose appropriate devices for patients with heart failure at high risk for arrhythmic death

Supported by an educational grant from Boston Scientific

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Moderators: Michael G. Petty
                   Timothy B. Icenogle

Obtaining Consent: What Do You Tell Patients and Families Considering VAD Therapy?

3:30 PM
Setting Expectations: Education or Sales?
Jeffrey J. Teuteberg

3:40 PM
What if They Say No? Palliative Care Options
Kristen G. Schaefer

3:50 PM
Caregiver Commitment: What Does Support Entail?
AnnMarie Kaan

4:00 PM
Discussion

How High is The Bar For a "Good" Destination?

4:10 PM
What Predicted Survival is a "Good" Destination?
Michael M. Givertz

4:20 PM
What Level of Adverse Events is Acceptable?
Robert L. Kormos

4:30 PM
What Qualify of Life makes a "Good" Destination?
Suzanne Chillcott

4:40 PM
Discussion

Going Home: Support Outside the Hospital

4:50 PM
The VAD Community on Line: MyAD.com
Steven W. Boyce

5:00 PM
What is the Social Support Necessary For VAD Success?
Michael G. Petty

5:10 PM
Discussion

Programmatic Issues

5:20 PM
Adjusting Antiocoagulation: Striking a Balance to Prevent Embolic Stroke And GI Bleeds
Ranjit John

5:30 PM
What is a Sustainable Ratio of VAD Coordinators to Patients: In New and Established Programs
Dawn M. Christensen

5:40 PM
Discussion

Learning Objective: Identify factors important to the success of VAD therapy and how to manage them.

Chair: Javed Butler

6:45 AM
Introductions
Javed Butler

6:50 AM
Nitric Oxide Pathobiology and Heart Failure
Douglas Mann

7:00 AM
Evidence Supporting the Benefit of H-ISDN in the Treatment of HF
Eldrin Lewis

7:10 AM
Guideline Recommendations and Clinical Use of H-ISDN
Gregg Fonarow

7:20 AM
Unanswered Questions and Future Research
Javed Butler

7:30 AM
Audience Questions and Panel Discussion
Faculty

Learning Objectives:

1. Describe clinical trial evidence and practice guidelines supporting the use of H-ISDN in patients with heart failure
2. Describe nitric oxide pathobiology in heart failure
3. Identify potential barriers to the effective use of H-ISDN in patients with heart failure and strategies for addressing these barriers
4. Describe the role of H-ISDN in the treatment of non-blacks and women with HF, pulmonary hypertension, and acute HF
5. Describe bioequivalence data of combination H-ISDN and generic preparations
6. Discuss ongoing research and quality of care initiatives with H-ISDN

Supported by an educational grant from Arbor Pharmaceuticals, Inc.

Although this program is not part of the scientific program as planned by the HFSA Program Committee, it has been reviewed and approved by the HFSA Satellite Program Committee.

Chair: Christopher O'Connor

6:45 AM
Introduction and Epidemiology of Sleep-Disordered Breathing in Heart Failure
Christopher O'Connor

6:50 AM
Pathophysiology of Sleep Apnea in the Heart Failure Patient
Daniel Gottlieb

7:05 AM
Sleep Apnea in Heart Failure: Key Elements of the Diagnostic Evaluation
William T. Abraham

7:15 AM
Treatment Strategies for Sleep Disordered Breathing in Heart Failure Patients
John S. Floras

7:30 AM
Troubleshooting in the Management of Heart Failure Patients with Sleep Disordered Breathing
Sara Paul

7:35 AM
Panel Discussion and Q & A
Faculty

Learning Objectives:

1. Identify the epidemiology and risk factors for sleep disordered breathing in heart failure patients
2. Discuss the mechanisms and pathophysiology of sleep-disordered breathing in patients with heart failure
3. Conduct an effective diagnostic work-up
4. Use appropriate treatment strategies for heart failure patients with sleep-disordered breathing

Supported by an educational grant from ResMed

Although this program is not part of the scientific program as planned by the HFSA Program Committee, it has been reviewed and approved by the HFSA Satellite Program Committee.

Moderators: Lynne Warner Stevenson
                   Thomas Force

8:40 AM
Feedback Loops Wired to Change Biology
Thomas Goetz

9:20 AM
Reaching Out for the Words
Billy Collins

Learning Objective: Describe ways in which communication at the personal, biological, and technological levels affect healthcare.

Moderators: Jay N. Cohn
                   Barry H. Greenberg

10:30 AM^*
Warafarin Versus Aspirin Patients with Reduced Cardiac Ejection Fraction (WARCEF) Trial
Shunichi Homma

10:47 AM
Commentary
John G.F. Cleland

10:52 AM^*
A Phase II, Randomized, Double-Blin, Multi-Center Placebo Controlled Study of a Cross-Linked Polyelectrolyte (CLP vs. Placebo in Heart Failure Patients with Chronic Kidney Disease)
Barry Massie

11:04 AM
Commentary
Steven Gottlieb

11:09 AM^*
Current Clinical Experience with the Synergy® Micro-Pump System in Chronic Ambulatory Heart Failure
Daniel Burkhoff

11:21 AM
Commentary
Robert L. Kormos

11:26 AM^*
Improving Self-Care Behavior and Clinical Outcomes in Rural Patients with Heart Failure
Kathleen Dracup

11:38 AM
Commentary
Barbara J. Riegel

11:43 AM^*
PARAMOUNT for Preserved EF Heart Failure
Scott D. Solomon

11:55 AM
Commentary
Margaret Redfield

^* 17 minutes allotted: 12 minute presentation, 5 minute commentary

Learning Objective: Describe the results of recent trials and discuss their implications for the care of patients with heart failure.

Moderators: Victoria Vaughan Dickson
                   Susan J. Pressler

10:30 AM^*
Discordance Between Self-Reported and 24-Hour Urine Sodium Intake and Predictors of Sodium Non-Adherence
Ruth M. Masterson Creber

10:48 AM^*
The Relationship Between Uric Acid and Inflammatory Markers Differ Between Heart Failure Patients with and without Central Obesity
Kyoung Suk Lee

11:06 AM^*
Patients with Biventricular Mechanical Support Can Be Safely Discharged to Home to Await Heart Transplant
J.W. Creaser

11:24 AM^*
Superior Perceived Control Comes with Improved Health Related Quality of Life in Younger Heart Failure Patients
Tsuey-Yuan Huang

11:42 AM^*
Lactic Acidosis After Cardiac Transplantation: Foe or Common Innocent Bystander?
Jennifer L. Nixon

^* 18 minutes allotted: 10 minute presentation, 8 minute audience discussion

Learning Objective: Discuss results of recent nursing research and its implications for the care of pts with HF.

Moderators: Marvin A. Konstam
                   W. Robb MacLellan

10:30 AM
A Perfect Cycle
Ann Bolger

10:40 AM
Metabolism Through NMR
Rong Tian

10:55 AM
Shifting Substrates-PET
James H. Caldwell

11:05 AM
Cardiac Magnetic Resonance Imaging Determines Etiology and Viability
Daniel Lee

11:15 AM
MIBG Imaging to Track Therapies and Prognosis
James H. Caldwell

11:30 AM
The Picture of Myocardial Inflammation
Peter P. Liu

11:45 AM
Questions and Answers
Faculty

Learning Objective: Identify imaging modalities and their appropriate use in the evaluation and management of patients with heart failure.

Moderators: Annarosa Leri
                   Douglas W. Losordo

10:30 AM
Why Do We Need iPS Cells if We Have Adult Cardiac Stem Cells?
Ronglih Liao

10:40 AM
Why Do We Need Adult Cardiac Stem Cells if We Have iPS Cells?
Charles E. Murry

10:55 AM
Questions

11:00 AM^*
Human iPS Cell-Based Therapy: Considerations Before Clinical Applications
Joseph Wu

11:18 AM^*
Alternative Use of Human iPS Cells: Drug Screening and Disease Modeling
Lior Gepstein

11:36 AM^*
Can We Reprogram Cardiac Fibroblasts Into New Cardiac Myocytes
Victor J. Dzau

^* 15 minute presentation, 2-3 minute audience discussion

Learning Objective: Describe the role and importance of iPS cells and adult stem cells in heart failure research and drug testing.

Moderators: Gary S. Francis
                   Peter P. Liu

12:30 PM^*
The Frequency and Prognosis of Cardiotoxicity from Trastuzumab
Jennifer R. Brown

12:35 PM^*
Do Risk Models in Advanced Heart Failure Need to be Sex-Specific?
Jennifer Chyu

12:40 PM^*
Sex Differences in Mortality on Waiting List for Heart Transplantation
Eileen Hsich

12:45 PM^*
Antibody-Mediated Rejection in Heart Transplantation: Does Induction and the Type Matter?
Z. Lill

12:50 PM^*
Therapeutic Targeted Delivery of AAV9 Sh BNIP3 Reverses Cardiac Remodeling and Improves Diastolic and Systolic Function in a Rat Model of Pressure Overload Induced Heart Failure
Antoine H. Chaanine

12:55 PM^*
HDAC Inhibition Reduces Infarct Size in Large Animal Ischemia/Reperfusion by Normalizing Cardiomyocyte Autophagy
Min Xie

1:00 PM^*
Altered Forms of Brain Natriuretic Peptide in Cardiac Disease
Jeffrey Chan

1:05 PM^*
Acute Subcutaneous and Oral Delivery of Cenderitide, a Novel Dual Natriuretic Peptide Receptor Agonist, Is Readily and Activates the Second Messenger CGMP
John C. Burnett

1:10 PM^*
Cognitive Function in Older Heart Failure Patients is Similar to Older Patients Following Stroke
Karen Harkness

1:15 PM^*
Pumped Up, But Not Prepared: Examining LVAD-DT Patients' Comprehension of Advance Directive Specifications
James Kirkpatrick

1:20 PM^*
Patient Perception of Physician-Patient Communication At Time of Implantable Defibrillator Implant Decision
Paul J. Hauptman

1:25 PM^*
Lipopolysaccharide Responsiveness Is an Independent Predictor of Death in Chronic Heart Failure
Nicole Ebner

1:30 PM^*
Quantifying Circadian Variation of Multiple Physiologic Signals in Ambulatory Heart Failure Patients
John Boehmer

1:35 PM^*
Short and Long-Term Outcome of Impedance-Guided Preemptive Therapy Provided to Prevent Pulmonary Congestion-Edema in the Course of Acute Myocardial Infarction
Michael Shochat

1:40 PM^*
Night-Time Elevation Angles in MultiSENSE Study Are Related to Symptoms of Orthopnea & Paroxysmal Nocturnal Dyspnea
John Hatlestad

^* 3 minutes to present, 2 minute discussion

To learn more about these studies, visit their posters during the poster presentation session in the Exhibit Hall.

Learning Objective: Discuss findings from recent clinical research in heart failure.

1. How to Identify Treatable Causes of Heart Failure
   
   Michael M. Givertz
   David E. Lanfear

Learning Objective: List treatable causes of heart failure and describe clinical techniques and procedures to identify them.


2. How to Bridge Patients to Transplantation with VADS
   
   Michael A. Acker
   Josef Stehlik

Learning Objective: Identify clinical issues in the management of patients with VADs awaiting transplant and how they can best be managed.


3. How to Maximize Adherence to Heart Failure Performance Measures in the Inpatient and Outpatient Settings
   
   Marc A. Silver
   May N. Walsh

Learning Objective: Identify heart failure performance measures and describe strategies for maximizing adherence in the inpatient and outpatient settings.


4. Using Tools for Economic Analysis of Management Interventions
   
   Shelby D. Reed
   Sara C. Paul

Learning Objective: Use tools to analyze the cost and cost-effectiveness of management interventions in heart failure.


5. Difficult Conversations About Prognosis
   
   Kristen G. Schaefer
   Harleah G. Buck

Learning Objective: Describe strategies for productive discussions with heart failure patients facing a difficult prognosis.

Moderators: James N. Kirkpatrick
                   Corrine Y. Jurgens

2:00 PM^*
Where Does Disease Management Take Place?
John B. O'Connell

2:18 PM^*
Device Management
Rachel J. Lampert

2:36 PM^*
When to Hold, When to Fold
Ali Ahmed

2:54 PM^*
Exercise Guidelines for Heart Failure in Nursing Homes
Ross Arena

3:12 PM^*
Promoting Self-Care in Patients Discharged Home From a Skilled Nursing Facility
Colleen Delaney

^* 15 minute presentation, 3 minute audience discussion

Learning Objective: Describe strategies for the effective evaluation and management of patients with heart failure in nursing homes.

Moderators: Robert Lee Page, II
                   Mona Fiuzat

2:00 PM^*
Testing New HF Drugs in Animal Models
Hani N. Sabbah

2:15 PM^*
Pharmacokinetics: Heart Failure Impacts on Drug Metabolism
Robert Lee Page, II

2:30 PM^*
Drug-Drug Interactions: Pumps, Proteins, and P-450s
Jo Ellen Rodgers

2:45 PM^*
Pharmacodynamics: Drug-induced QT Prolongation: Is It a Concern?
Tien M.H. Ng

3:00 PM^*
Adapting Drug Regimens for the Elderly
Michael W. Rich

3:15 PM^*
Supplements or Prescriptions? PUFAs and Others
Barry H. Greenberg

^* 12 minute presentation, 3 minute audience discussion

Learning Objective: Describe the pharmacology of heart failure drugs and its implications for patient management.

Moderators: Ileana L. Piña
                   Marc J. Semigran

(10 Knowledge Points: Must attend both sessions to earn points)

Learning Objective: Discuss key questions in the epidemiology, pathophysiology, and treatment of patients with advanced heart failure.

Moderators: Jay N. Cohn
                   Barry H. Greenberg

2:00 PM^*
Diabetes and Left Ventricular Function: A Population Based Study in Olmsted Country, MN
Sanjay Dandamudi

2:18 PM^*
Circulating Molecular Forms of C-Type Natriuretic Peptide in Aging Humans and Their Biological Actions in Cultured Human Cardiac Fibroblasts: A Potential Therapeutic and Diagnostic Opportunity
S. Jeson Sangaralingham

2:36 PM^*
All Three NP Pre/Prohormones Are Processed in Normal Human Blood into Biologically Active Mature Peptides
Tomoko Ichiki

2:54 PM^*
Safety and Prognostic Value of Cerebral Oximetry Monitoring in Heart Failure Patients During Cardiopulmonary Exercise
Luay Rifai

3:12 PM^*
The Association Between Nursing Home Care Quality and 30-Day Readmission Rates after Hospitalization for Heart Failure
Owolabi Ogunneye

^* 10 minute presentation, 8 minute audience discussion

Learning Objective: Discuss results of recent research and their implications for the treatment of heart failure.

Moderators: Eldrin F. Lewis
                   Mary A. Woo

2:00 PM
Night and Day: Hemodynamic Rhythms During Ambulatory Monitoring
Philip B. Adamson

2:10 PM
FEATURED LECTURE: Diurnal Rhythms at the Translational (or Molecular) Level
Michael J. Sole

2:30 PM
Medication Schedules to Optimize Adherence and Benefit
Michael D. Murray

2:40 PM
Discussion

2:45 PM
Optimal Frequency and Intensity of Exercise
Daniel Forman

3:00 PM
Family Dynamics
Susan J. Pressler

3:15 PM
Circadian Rhythms and Sleep-Disordered Breathing
James C. Fang

3:25 PM
Questions and Answers

Learning Objective: Use circadian rhythms and other time-based strategies to maximize management of the patient with heart failure.

Moderators: Walter J. Koch
                   J. Herbert Patterson

2:00 PM^*
Challenges in Beta-Blocker Utilization: Counting the Eligible
Adrian F. Hernandez

2:18 PM^*
Biased Downstream Signaling
Burns C. Blaxall

2:36 PM^*
Next Generation Beta-Blockers for Heart Failure: Isoform Specific Targeting
Michael R. Bristow

2:54 PM^*
Genetic Diversity in Beta-Blocker Therapy
Thomas P. Cappola

3:12 PM^*
Beta Blockers: A Class Effect?
Steven S. Gottlieb

^* 15 minute presentation, 3 minute audience discussion

Learning Objective: Describe emerging ways in which the effectiveness of beta-blocker therapy for heart failure might be increased.

Moderators: Peter E. Carson
                   Randall C. Starling

4:00 PM
Get with the Guidelines: Does Adherence Assure Quality Outcomes?
Gregg C. Fonarow

4:15 PM
MRAs: What is the Evidence to Support Their Use
Bertram Pitt

4:30 PM
MRAs: What are the Gaps in Adoption?
Mary N. Walsh

4:45 PM
HFSA 2012 Recommendations on the use of MRA
Javed Butler

5:00 PM
Panel Discussion and Case Studies

Javed Butler
Peter E. Carson
Gregg C. Fonarow
Bertram Pitt
Randall C. Starling
Wendy Gattis Stough
Mary N. Walsh
Cheryl A. Westlake

Case #1: A 70 yo African American male with EF 30%, NYHA Class III. What is the best to add next?
Presenter: Nancy K. Sweitzer

Case #2: A 35 yo diabetic male post-MI with EF 36% Impaired renal function. What is the best to add next and how to monitor?
Presenter: Monica Colvin-Adams

Learning Objective: Identify updates and clinical applications of guidelines for the treatment of patients with heart failure.

Moderators: John G.F. Cleland
                    Mariann R. Piano

4:00 PM^*
HbA1C and Heart Failure: Targets for Diabetes in Heart Failure
David Aguilar

4:15 PM^*
BMI and Heart Failure: To Gain Weight or Lose it?
Stefan D. Anker

4:30 PM^*
Blood Pressure in Heart Failure: Sign of Pump or Sign of Load?
Biykem Bozkurt

4:45 PM^*
Contractility: It Has To Be Just Right
Steven R. Houser

5:00 PM^*
ICD Benefit and Disease Severity in Heart Failure
Leslie A. Saxon

5:15 PM^*
Iron and Erythropoietin in Heart Failure: What is Too Much?
Inder S. Anand

^* 12 minutes with 3 minute discussion after each presentation

Learning Objective: Describe a common pattern in diverse management issues and how it provides guidance for optimum patient care.

Moderators: Kenneth B. Margulies
                   Thomas P. Cappola

4:00 PM^*
Common Heritable Mutations in CM
Ray E. Hershberger

4:18 PM^*
GWAs (Genome - Wide Association Studies) for Dummies
Thomas J. Wang

4:36 PM^*
Genes Causing both CM and Arrhythmias
Calum A. MacRae

4:54 PM^*
Correlating Genotype with Phenotype in Cardiomyopathies
Sharlene M. Day

5:12 PM^*
Whole Genome Strategies for Cardiomyopathy
Elizabeth M. McNally

^* 15 minute presentation, 3 minute audience discussion

Learning Objective: Discuss current research in the role of genetics in the development of cardiomyopathy and its implications for clinical practice.

Moderators: Claire Hunter
                   Alan B. Miller

4:00 PM
Reducing Readmissions: What Can We All Agree On?
Leora Horwitz

4:10 PM
Does Very Early Follow-up Make a Difference?
Robin J. Trupp

4:20 PM
Paving the Road Through Rehabilitation
Michael G. Dickinson

4:30 PM
Questions on the Transition

4:50 PM
Assessment and Impact of Frailty
JoAnn Lindenfeld

5:00 PM
Management in Montreal
Anique Ducharme

5:10 PM
Where is the Medical Home for Medicare Patients With Heart Failure and Co-Morbidities?
Douglas D. Shocken

5:20 PM
Discussion

Learning Objective: Identify factors affecting the transition from hospital to home for patients with heart failure and describe ways to manage them.

Moderators: Ileana L. Piña
                   Marc J. Semigran

(10 Knowledge Points: Must attend both sessions to earn points)

Learning Objective: Discuss key questions in the epidemiology, pathophysiology, and treatment of patients with advanced heart failure

Moderators: Walter J. Koch
                   W. Robb MacLellan

4:00 PM^*
Induction of Native Cardiomyocyte Cell Cycle Re-Entry by Transplanted Cells as a Novel Mechanism of Therapeutic Regeneration in the Heart
Konstantinos Malliaras

4:18 PM^*
Cardiac Specific Overexpression of Nrf2 Protects Against Pressure Overload-Induced Heart Failure Via Enhancing Autophagic Clearance of Ubiquitinated Proteins
Wenjuan Wang

4:36 PM^*
MEK7-JNK1-Akt Signaling Axis Regulates Phospholamban-^T17 Phosphorylation and Intracellular Calcium Levels in an Anthrax Model of Acute Diastolic Heart Failure
Honey B. Golden

4:54 PM^*
Metoprolol Enhances Caveolae-Localized NO-cGMP Signaling in Volume-Overloaded Hearts
Emily J. Tsai

4:12 PM^*
Full Expression of Acute Non-Ischemic Cardiomyopathy in a Murine Model Is Dependent on Intact B Cell Function
Anrea M. Cordero-Reyes

^* 10 minute presentation, 8 minute audience discussion

Learning Objective: Discuss the results and implications of basic science research in heart failure.

Chair: Clyde W. Yancy

7:00 AM
Welcome and Introduction: The Scope of the Problem
JoAnn Lindenfeld

7:05 AM
Current Guidelines for the Management of Mitral Regurgitation in Patients with Heart Failure: What Are They and Are They Being Followed?
Robert Bonow

7:20 AM
High Risk Patients with Mitral Regurgitation: Severe LV Dysfunction and Comorbidities
Steven Bolling

7:35 AM
Percutaneous Therapies for Mitral Regurgitation: Current Data and Future Possibilities
John Carroll

7:50 AM
Panel Discussion
Faculty

Learning Objectives:

1. Define specific types of mitral regurgitation
2. Identify guidelines for the management of mitral regurgitation (MR) in patients with heart failure
3. Identify ambiguous terms or areas not explicitly addressed by the guidelines
4. Describe high risk patients with MR, follow appropriate treatment strategies for managing MR in patients with heart failure
5. Discuss emerging therapeutic options in the treatment of MR in patients with heart failure

Supported by an educational grant from Abbott Vascular

Although this program is not part of the scientific program as planned by the HFSA Program Committee, it has been reviewed and approved by the HFSA Satellite Program Committee.

Moderator: Clyde W. Yancy

7:00 AM
The View from Washington
Marvin A. Konstam
Barry H. Greenberg

7:15 AM
How Many Patients, How Many Staff?
Mariell L. Jessup

7:23 AM
Nurses, Nurse Practitioners, or Physician Assistants
Suzanne J. Wingate

7:31 AM
What Costs for Transplant and VADS are Sustainable?
Joseph G. Rogers

7:39 AM
The Michigan Model
Keith D. Aaronson

7:47 AM
The VA System as a Database Model
Barry M. Massie

7:55 AM
Panel Discussion

Learning Objective: Identify factors affecting the transition from hospital to home for patients with heart failure and describe ways to manage them.

Moderators: Daniel J. Lenihan
                   Ayan R. Patel

7:00 AM
CRT - Wider Indications, Wider QRS
Jagmeet P. Singh

7:10 AM
ICD-Common and Uncommon Indications and Complications
Sanjiv Narayan

7:20 AM
ICD Shocks: Evaluating and Secondary Prevention
William G. Stevenson

7:30 AM
Device Questions

7:40 AM
Evaluation of Pulmonary Hypertension and Right Ventricular Function
Myung H. Park

7:50 AM
Specific Causes of Pulmonary Hypertension
Teresa De Marco

8:00 AM
Newer Management of Primary and Secondary Pulmonary Hypertension
Robert Frantz

8:10 AM
Questions

Learning Objective: Describe strategies for care of the patient with advanced heart failure, including mechanical circulatory support and transplantation.

Moderators: Sharon A. Hunt
                   Leslie W. Miller

8:30 AM
Referral to Advanced Heart Failure Programs
Mark J. Zucker

8:40 AM
Significance of ICD Shocks for Prognosis
Jeanne E. Poole

8:50 AM
Listing for Transplant Depends on Length of List
Mario C. Deng

9:00 AM
Serial Monitoring of the Right Ventricle During HF Progression
Paul R. Forfia

9:10 AM
Not Too Sick or Too Well for a VAD
Michael A. Acker

9:20 AM
Discussion

9:30 AM
Preventing Rejection and Vasculopathy Without Infection or Cancer
David O. Taylor

9:40 AM
Questions

9:45 AM
Too Soon or Too Late for the Hospice Discussion
Kelly Ann Light-McGroary

9:55 AM
Questions

Learning Objective: Describe approaches to key management decisions in care of the patient with advanced heart failure.

Moderators: William G. Stevenson
                   Jagmeet P. Singh

8:30 AM
Prevalence of Atrial Fibrillation in HF All EF
Denis Roy

8:45 AM
Anticoagulation in AF: Dosing New and Old
Michael D. Ezekowitz

9:00 AM
Anxiety Sensitivity and Benefit of AF Rhythm Control
Mario Talajic

9:15 AM
Questions

Three Approaches to Atrial Fibrillation

9:20 AM
Anti-arrhythmic Drugs and Rate Control
William G. Stevenson

9:30 AM
Ablation of the Atrial Fibrillation
Sanjiv Narayan

9:40 AM
AV Node Ablation and CRT
Bruce L. Wilkoff

9:50 AM
Discussion

Learning Objective: Recognize clinical issues in the care of patients with atrial fibrillation and choose the best management options.

Moderators: Biykem Bozkurt
                   Bertram Pitt

8:30 AM
Hyponatremia: Marker or Target?
James E. Udelson

Point/Counter Point

8:40 AM
Sodium Restriction is Beneficial in Patients with Heart Failure
Stuart D. Katz

8:50 AM
Sodium Restriction Can Be Harmful in Patients with Heart Failure
Giuseppe Licata

9:00 AM
Discussion

9:05 AM
Can We Develop a Drug to Diminish Thirst?
Robert J. Cody

9:22 AM
Discussion

9:25 AM
Fluid Restriction in Patients with Heart Failure: When is it Needed?
J. Thomas Heywood

9:45 AM
One Size Does Not Fit All
Terry A. Lennie

9:55 AM
Questions

Learning Objective: Discuss what is known about the role of sodium restriction in heart failure and selected strategies for successful implementation.

Moderators: Katherine J. Hoercher
                   Mark D. Sullivan

8:30 AM
How Does EF Affect the Symptoms of Heart Failure?
Michael R. Zile

8:40 AM
Who Knows Best? Using The Patient Symptom Report
Corrine Y. Jurgens

8:50 AM
I am Short of Breath - Clinical and Hemodynamic Diagnosis
Stuart D. Russell

9:05 AM
BNP Fragments: Potent or Passengers?
Horng H. Chen

9:15 AM
Discussion of Diagnosis

9:20 AM
Tracking Changes at Home
Eugene S. Chung

9:35 AM
PDE-5 Inhibitors - Treating the Disease or the Symptoms?
Gregory D. Lewis

9:45 AM
Symptom Burden and Palliation
James N. Kirkpatrick

9:55 AM
Questions

Learning Objective: Describe the physiological basis of heart failure symptoms and the role of selected symptoms in patient care.

Moderators: Burns C. Blaxall
                   Douglas L. Mann

8:30 AM^*
Contractility Modulation or Smaller Assist Devices for Earlier Use?
Daniel Burkhoff

8:45 AM^*
Autonomic Modulation - For The Periphery or The Heart?
Mark E. Dunlap

9:00 AM^*
New Targets for Inotropic Therapy
Walter J. Koch

9:15 AM^*
How Can Negative Inotropic Agents Improve Cardiac Function
Joshua I. Goldhaber

9:30 AM^*
IV Inotropic Therapy at Home
Lenore J. Blank

9:45 AM^*
Can CaMKII Inhibitors Affect the Function of the Failing Heart?
Donald M. Bers

^* 12 minute presentation, 3 minute discussion

Learning Objective: Describe ways in which emerging devices and inotropic therapy can impact cardiac function in heart failure.

Case Presenters: Lynne V. Doering
                           Javed Butler

8:30 AM^*
Randomized Controlled Trial of a Biobehavioral Intervention for Depression in Patients with Heart Failure
Debra K. Moser

8:45 AM^*
Marked Changes in Right Ventricular Contractile Pattern After Cardiac Surgery May Be Secondary to Pericardial Incision: Implications for the Post-Surgical Assessment of Right Ventricular Function
Amresh Raina

9:00 AM^*
Metformin, But Not Diet-Induced Weight Loss, Decreases Myocardial Fibrosis in a Murine Model of Diet-Induced Insulin Resistance and Cardiomyopathy
Tomasz Wietecha

9:15 AM^*
Algisyl-LVR Reduces Left Ventricular Wall Stress and Improves Function in the Failing Human Heart
Julius Guccione

9:30 AM^*
Cardiac Specific Gene Delivery of a Dual GC-A and GC-B Agonist, CD-NP, Mediates Anti-Hypertrophic Actions in a Model of Hypertensive Heart Disease Beyond GC-A Activation Alone Via BNP
Alessandro Cataliotti

9:45 AM^*
Discordance Between Peak Metabolic Demand and LVAD Flow Rate During Upright Symptom-Limited Exercise
Dennis J. Kerrigan

^*15 minutes each (10 minute presentation, 5 minutes discussion)

Learning Objective: Discuss findings from recent research in heart failure and their implications for heart failure research and treatment.

Case Presenters: James C. Fang
                         Gary S. Francis

10:30 AM
Case #1
A 27 y/o healthy mother delivers a healthy infant who quickly develops a severe, dilated cardiomyopathy and undergoes successful heart transplantation at one month of age. During this time the mom develops symptoms of early heart failure and the echo indicates features of an early, mild, dilated cardiomyopathy (LVED=58mm and the EF=42% with global hypokinesis). The mother, an RN, asks you whether she has post-partum cardiomyopathy, or if she has familial dilated cardiomyopathy.

10:52 AM
Case #2
An 18 y/o high school All-American basketball player from Chicago comes to see you because he felt lighted on the basketball court during the game. All the findings are consistent with HCM, but there is no LVOT obstruction at rest or during provocation or maximal exercise. There are no risk factors for sudden death. A MRI indicates minimal fibrosis of the heart. He has a full scholarship to Kentucky, Michigan and Duke. His local cardiologist, a well-known professor in Chicago, strongly believes that the patient should have an ICD and be allowed to play in college, and his parents also favor this pathway. The patient wants your opinion.

11:14 AM
Case #3
75 y/o man is admitted for 3rd time with appropriate ICD shocks. Underwent previous CABG 5 yrs ago, all grafts patent. Underwent VT ablation last admission; on amiodarone. RHC notable for RA 6, PCW 18, PA 45/20/25, CI 2.1. Echo EF 15% , EDD 7.0 cm. BUN 35, Cr 1.5. Patient maintains he is NYHA II between shocks. Primary cardiologist suggests LVAD after hearing your recent CME talk about LVADs.

11:36 AM
Case #4
60 year old women is referred for coronary angiography for new onset heart failure. Has been NYHA II-III for past month. Echo shows EF 25%, moderate MR, EDD 6.5 cm. No angina. Initiated on lisinopril 5 mg, bisoprolol 2.5 mg, furosemide 40 mg. Cath shows 70% mid LAD, 80% ramus, and 90% lesion in proximal dominant RCA. RHC notable for RA 12, PCW 22, PA 50/25/30 , CI 2.4. Interventionalist pages you to let you know he is ready to stent RCA. Husband wants patient to see senior cardiac surgeon he personally knows.

11:58 AM
Case #5
A 37 y/o woman blood type O with advanced dilated cardiomyopathy (EF=22%, NYHA Class III) is referred to you for management. There are two issues that the referring physician wants you to clarify: The patient has a dilated LV with an LVIDd of 64 mm, and severe 4+ MR with restricted mitral valve leaflet motion. The PVR, TPG and PA pressure indicate she is an acceptable transplant candidate. Can or should MV be considered for repair? The other problem is that she is not tolerating her medications (carvedilol, lisinopril, spironolactone, and furosemide) very well due to symptomatic hypertension. These are being down-titrated. How does one down-titrate? He ask you "is it time for an LVAD"? He is from the Univ. of Michigan where MV repair for severe MR and a low EF is frequently performed.

Panelists:
Michele A. Hamilton
Soon J. Park
Patricia A. Uber
Sara C. Paul
Mario Talajic

Learning Objective: Using practice guidelines, research findings and clinical experience, make decisions about the management of difficult cases in heart failure.

Moderators: Michael A. Portman
                   Rong Tian

10:30 AM^*
Metabolic Remodeling in Human Heart Failure
Robert J. Gropler

10:48 AM^*
Novel Metabolic Therapies on the Horizon?
E. Douglas Lewandowski

11:06 AM^*
Mitochondrial Metabolism in HF
W. Robb MacLellan

11:34 AM^*
Metabolic Therapeutics in the Failing Heart
Robert G. Weiss

11:52 AM^*
Perturbations of Mitochondrial Proteome in the Failing Myocardium
Peipei Ping

^* 15 minutes each (10 minute presentation, 3 minutes discussion

Learning Objective: Describe the role of cardiac metabolism in remodeling and cardio-protection and the role of emerging metabolic therapies.

Moderators: Mihai Gheorghiade
                   TBN

10:30 AM
Overview of the Issues
Mihai Gheorghiade

10:35 AM
Industry Point of View: Impediments and Challenges to Bringing New Heart Failure Drugs and Devices to Market
Stuart Kupfer, Frank Misselwitz, Arjun Sharma

11:05 AM
FDA Point of View: Regulatory Issues
Preston Dunnmon, Felipe Aguel

11:25 AM
The Payer's Perspective
TBD, TBD

11:45 AM
Panel Discussion

Learning Objective: Describe the role of national policies on the development of new heart failure therapies in the US and Europe and discuss ways to enhance research and development.

Moderators: Stefan D. Anker
                   Barry M. Massie

Role of Anti-Myocardia Abs: Cause or Result of Injury?

10:30 AM
Anti-myocardial Antibodies and Persistent Virus in Cardiomyopathy
Carsten Tschöpe

10:45 AM
The Role of Biopsy and Testing for Antibodies
Peter P. Liu

11:00 AM
Discussion

Recovery is Real with VADs

11:15 AM European Experience with VAD Recovery - Different Patients or Different Patience?
Piotr Ponikowski

11:30 AM US Experience with Recovery
Simon Maybaum

11:45 AM
Discussion

Learning Objective: TBD

Moderators: Blasé A. Carabello
                   Robert L. Kormos

10:30 AM
The Low Gradient Low EF AS Patient
Philippe Pibarot

10:45 AM
Dogs and People with Functional MR
Blasé A. Carabello

11:00 AM
The Patient with Advanced AR
Jeffery S. Borer

11:15 AM
The Patient with Valvular Heart Disease and Lung Disease: When Will Fixing the Valve Fix the Dyspnea?
Barbara A. Cockrill

11:30 AM Can I Ignore TR in My Patient with Left-Sided Valvular Heart Disease?
Edwin C. McGee, Jr.

11:45 AM
Panel Discussion

Learning Objective: Describe surgical approaches to the heart failure patient with valvular disease.

Moderators: Arthur M. Feldman
                   Carl V. Leier

12:30 PM^*
Results of the RISK Trial: Renal Function and Female Gender Are Strongly Associated with Early Response to Cardiac Resynchronization Therapy
Alaa A. Shalaby

12:35 PM^*
The Impact of Isolated Diastolic Dysfunction on Atrial Fibrillation Recurrence After Catheter Ablation
Rosita Zakeri

12:40 PM^*
Tetrahydrobiopterin Improves Diastolic Heart Failure by Increasing Myofilament Calcium Sensitivity
Euy-Myoung Jeong

12:45 PM^*
Activation of Pulmonary Arterial Endothelium in Heart Failure with Preserved Ejection Fraction Induced Pulmonary Hypertension Similar to Pulmonary Arterial Hypertension
Jason N. Salamon

12:50 PM^*
Therapy with a DPP-4 Inhibitor Increases Myocardial Glucose Uptake in Nonischemic Cardiomyopathy
Ronald M. Witteles

12:55 PM^*
Urokinase Induces Pro-Fibrotic/M2 Phenotype in Cardiac Macrophages
April Stempien-Otero

1:00 PM^*
Incidence, Predictors and Outcomes Related to Hypo and Hyperkalemia in Severe Heart Failure Patients Treated with an Aldosterone Antagonist
Orly Vardeny

1:05 PM^*
Inpatient Initiation and Target Dosing of ACE Inhibitors and Beta-Blockers in Children with Heart Failure
Jack F. Price

1:10 PM^*
Adverse in-Hospital Outcomes by Systolic Blood Pressure at Admission in Patients Hospitalized with Acute Heart Failure Syndromes - Data from RO AHFS Registry
Andrew Ambrosy

1:15 PM^*
The Timing of Hemoconcentration During Treatment of Decompensated Heart Failure Influences Subsequent Survival
Meredith A. Brisco

1:20 PM^*
Stimulation of β₂ Adrenergic Receptors Clears Lung Fluid in Patients with Heart Failure
Bryan J. Taylor

1:25 PM^*
Obesity Paradox Does Not Apply to Acute Heart Failure
Maya Guglin

^* 3 minutes to present, 2 minute discussion

To learn more about these studies, visit their posters during the poster presentation session in the Exhibit Hall.

Learning Objective: Discuss findings from recent research in HF and their implications for heart failure research and treatment.

6. Using Apps for Self-Care
   
   Jill Howie Esquivel
   Lorraine S. Evangelista

Learning Objective: Describe the role of electronic applications in patient self-management of heart failure.


7. Cardiotoxicity of Chemotherapy: Evaluation and Therapy
   
   Jean-Bernard Durand
   Anju Nohria

Learning Objective: Evaluate heart failure patients undergoing or recovering from chemotherapy and manage their disease.


8. How to Read and Interpret the Results of Genetic Testing
   
   Neal Lakdawala
   Daniel J. Jacoby

Learning Objective: Identify the components of genetic testing results, their meaning, and their implications for patient care.


9. How to Identify and Use Simple Tools for Assessment of Health Literacy
   
   Pamela N. Peterson
   Ann S. Laramee

Learning Objective: Identify and use tools to assess health literacy and improve care in patients with heart failure.


10. Heart Failure Physicians Learn to Read the ICD/CR Device Reports
    
    Bruce L. Wilkoff
    William H. Sauer

Learning Objective: To identify the components in the device reports most important for managing heart failure.

Moderators: John G.F. Cleland
                   Douglas D. Schocken

2:00 PM^*
Digoxin, Curse or Cure?
Mihai Gheorghiade

2:12 PM^*
Basic Science Does Not Matter: The Negligible Potential of Molecular Research
Eric S. Ambrecht

2:24 PM^*
Another New Training Program in Diastolic Predominant Heart Failure
Matthew Wheeler

2:36 PM^*
We Should Not Be Preventing Heart Failure
Jay N. Cohn

2:48 PM^*
Can Horse Drink the Water Please?
Narendra C. Bhalodkar

3:00 PM^*
An "Epic" Move to Automated Medical Documentation: Copying and Pasting Our Way Into Oblivion
Larry Allen

3:12 PM^*
Zen and the Art of Heart Failure
William G. Cotts

^* 9 minute presentation, 3 minute audience discussion

Learning Objective: Discuss new insights and perspectives on heart failure research, education, and clinical practice.

Moderators: Anita Deswal
                   Debra K. Moser

2:00 PM
Leading Up to Admission (ADHERE)
Javed Butler

2:15 PM
Why is the Patient Back?
Jason W. Ryan

2:25 PM
How is Comorbidity Associated with Readmission?
Jill Howie Esquivel

2:35 PM
What Else Can DOSE and ASCEND Teach Us?
G. Michael Felker

2:45 PM
ED Decision: Admit or Discharge to Early Follow-Up?
Peter S. Pang

3:00 PM
How Much Patient Education and When?
Lorraine S. Evangelista

3:15 PM
Panel Discussion

Learning Objective: Describe factors affecting readmission of patients with heart failure and implement strategies to improve readmission rates.

Moderators: Steven Goldman
                   Michael J. Sole

2:00 PM^*
Where is there a Clinical Need?
Arthur M. Feldman

2:18 PM^*
PKC Inhibitors are Ready for Heart Failure Trials!
Jeffrey D. Molkentin

2:36 PM^*
Enough with the Kinases; Phosphatase Inhibitors for Heart Failure Therapy
Yibin Wang

2:54 PM^*
Cell-Free Regenerative Therapies
Annarosa Leri

3:12 PM^*
Angiogenesis for Ischemic Heart Disease
Douglas W. Losordo

^* 15 minute presentation, 3 minute discussion

Learning Objective: Describe emerging therapies for heart failure and how they might be used to improve patient care.

Moderators: Paul R. Forfia
                   Robert P. Frantz

2:00 PM^*
Pulmonary Hypertension From HFpEF
Margaret M. Redfield

2:15 PM^*
Primary, Reactive or Passive Pulmonary Hypertension
Myung H. Park

2:30 PM^*
Lessons from Experimental Pulmonary Hypertension
Jane A. Leopold

2:45 PM^*
What Does the Right Ventricle Look Like?
Paul R. Forfia

3:00 PM^*
Animal Models of Right Ventricle Overload
Emily J. Tsai

3:15 PM^*
Right Ventricular Recovery
Mandeep R. Mehra

^* 12 minute presentation, 3 minute audience discussion

Learning Objective: Describe pulmonary hypertension and right ventricular failure and identify appropriate management options.

Moderators: Marvin A. Konstam
                   Lynne Warner Stevenson

DEBATE: Oral Inotropic Agents Should be Available for Palliative Care

4:00 PM
Pro: Milton Packer
Con: Milton Packer

4:30 PM
Questions from Moderators

DEBATE: Critical Care

4:45 PM
Clinical Care Should Focus More on Risk Stratification Tools^*
Wayne C. Levy

5:00 PM
Clinical Care Should Focus on More Tools For Assessing Quality of Life^*
Eldrin F. Lewis

^* Equal time should be given to all recognized tools.

5:15 PM^*
Questions from Moderators

Learning Objective: Outline considerations influencing the use of inotropic agents in palliative care and tools for assessing risk and quality of life in patients with heart failure.

Moderators: Nancy M. Albert
                   Mariell L. Jessup

4:00 PM
Impact of Performance Measures on Outcomes
Christopher M. O'Connor

4:10 PM
Heterogeneity of Performance
Gregg C. Fonarow

4:20 PM
Can We Adjust Populations to Measure Effectiveness?
Soko Setoguchi-Iwata

4:30 PM
When Guidelines Can Be Performance Measures
Frederick A. Masoudi

4:40 PM
What the Community Physician Needs to Know
Donald E. Casey, Jr.

5:00 PM
Strategy for Implementation of Outpatient Measures
Clyde W. Yancy

5:15 PM
Questions and Answers
Faculty

Learning Objective: Identify and assess current performance measures in heart failure and implement strategies for adherence.

Moderators: Michael R Bristow
                   Douglas L. Mann

4:00 PM
Changing Gene Expression with Medications
Peter Buttrick

4:15 PM
Changing Gene Expression with LVAD Support
Kenneth B. Margulies

4:30 PM
Questions

4:35 PM
The Dynamic Right Ventricle
Michael R. Bristow

4:50 PM
Questions

4:55 PM
What Happens to Ventricular Function with Heart Failure Self Care
Christopher S. Lee

5:10 PM
Hemodynamic Remodeling During Home Monitoring
William T. Abraham

5:25 PM
Questions

Learning Objective: Describe ways in which therapy can influence the genetic and physiological basis of heart failure and improve patient care.

Moderators: Robert Lee Page, II
                   Prakash C. Deedwania

4:00 PM
How Can Medication Adherence be Measured?
Patricia A. Uber

4:18 PM
Dosing Regimens
Michael D. Murray

4:36 PM
Predicting Nonadherence
Barbara J. Riegel

4:54 PM
Consequences of Poor Adherence
Paul J. Hauptman

5:12 PM
What Can We Do to Improve Adherence?
Debra K. Moser

Learning Objective: Measure patient adherence, identify variables contributing to non-adherence, and implement measures to improve adherence.

Moderators: Tamara B. Horwich
                   Josef Stehlik

7:00 AM
When Is It Appropriate to Consider Referral for Advanced Heart Failure Therapies?
Garrick C. Stewart

7:10 AM
A Bridge to What? Choosing the Right Destination
Jennifer Cowger

7:20 AM
Mechanical Circulatory Support: Complications and Troubleshooting
Michael A. Acker

7:35 AM
Cardiac Transplantation: Short and Long-Term Outcomes and Implications for Patient Selection
David DeNofrio

7:45 AM
Cardiac Transplantation: Individualizing Immune Suppression
Jon A. Kobashigawa

8:00 AM
Palliative Care and Shared Decision Making in Advanced Heart Failure
Sarah J. Goodlin

8:10 AM
Questions and Answers
Faculty

8:15 AM
Clinical Pearls
Carl V. Leier

Learning Objective: Evaluate heart failure patients for device implantation, manage implanted devices, and diagnose and treat pulmonary hypertension.

Moderators: Anju Nohria
                   Paul Rosenberg

8:30 AM^*
Why So Many Tyrosine Kinases?
Thomas Force

8:45 AM^*
Cardiac Effects of Cytokines
Douglas L. Mann

9:00 AM^*
Cardiomopathy of Substance Abuse
George G. Philippides

9:15 AM^*
Decreasing Toxicity of Anthracyclines
Douglas B. Sawyer

9:30 AM^*
Toxicity of Nitric Oxide
TBN

9:45 AM^*
Cardiac Risk of High Intensity Exercise
Joseph R. Libonati

^* 12 minute presentation, 3 minute audience discussion

Learning Objective: Evaluate heart failure patients for device implantation, manage implanted devices, and diagnose and treat pulmonary hypertension.

Moderators: Edward M. Gilbert
                   Jacob Joseph

8:30 AMCurrent Management Strategies in Peripartum Cardiomyopathies
Uri Elkayam

8:45 AM
Host Factors in Human Viral Cardiomyopathy
TBN

9:00 AM
Treatment of Thalassemia and Iron Load Cardiomyopathies: What is New?
JonDavid Menteer

9:15 AM
Prevention and Monitoring of Chemotherapy Induced Cardiomyopathies
Jean-Bernard Durand

9:30 AM
Rhythm Devices for Sarcoidosis
William H. Sauer

9:45 AM
Role of Registries for Specific Conditions
Panel Discussion

Learning Objective: Diagnose selected cardiomyopathies and evaluate available treatment strategies.

Moderators: Peter E. Carson
                   Mariann R. Piano

8:30 AM^*
Facing the Front Line: Use of Community Health Workers
Gia Mudd-Martin

8:43 AM^*
Integrating Care of Depression and Anxiety Into the Clinic
Jared L. Skillings

8:56 AM^*
Value Based Purchasing - Objects in Your Mirror Are Closer Than You Think!
Mitchell T. Saltzberg

9:10 AM
Old and New Biomarkers for Triage or Therapy?
Alan S. Maisel

9:23 AM
Update on Diuretic Infusions for Frequent Flyers
Marie Galvao

9:35 AM
Non-Invasive Monitoring is Most Effective
John G.F. Cleland

9:45 AM
Invasive Home Monitoring is Most Effective
Robert C. Bourge

9:55 AM
Questions

^* 10 minute presentation, 3 minute audience discussion

Learning Objective: Use home-based and community-based strategies to reduce readmission of the heart failure patient.

Moderators: Eugene Braunwald
                   Gordon W. Moe

10:30 AM
Autonomic Modulation With Devices
W.H. Wilson Tang

10:40 AM
The Leadless Defibrillator
Gust H. Bardy

10:50 AM
Questions

10:55 AM
Cardiology Patient Communities in Social Networks
Leslie A. Saxon

11:05 AM
Tracking Rate and Rhythm on Smart Phones
David E. Albert

11:15 AM
Questions

11:20 AM
Destination Therapy with Miniaturized Percutaneous VADs
Daniel Burkhoff

11:30 AM
Questions

11:35 AM
Bio-Nano-Chip Technology for Biomarker Assessment in Heart Failure
John T. McDevitt

11:45 AM
Implantable Monitoring Devices Close the Loop Directly With Patients
William T. Abraham

11:55 AM
Questions

12:00 PM
Comments: Vision for the Future: New and Renewed
Eugene Braunwald

Learning Objective: Discuss emerging devices and networks and their potential impact on care of patients with heart failure.

Moderators: Steven R. Goldsmith
                   Milton Packer

10:30 AM
Better Endpoints for New Therapies
John R. Teerlink

10:40 AM
Six Minute Walk for Pulmonary Hypertension, Why Not For Heart Failure?
Mandeep R. Mehra

10:50 AM
Questions

10:55 AM
Evidence for Improved Quality of Care
Nancy M. Albert

11:05 AM
Questions

11:08 AM
Prevalence and Prognosis of Heart Failure: Better EF
Akshay S. Desai

11:18 AM
Which Medications Can Be Stopped for Improvement and How?
Mark A. Munger

11:28 AM
Questions

11:35 AM
Defining A Good Death
Theo E. Meyer

11:45 AM
Evidence for Improving Survival in the Heart Failure Population
Jonathan G. Howlett

11:55 AM
Questions

Learning Objective: Reassess common care endpoint in the treatment of heart failure and determine optimal approaches to care and management.

Moderators: Biykem Bozkurt
                   Barbara J. Riegel

10:30 AM
Do Survival Models Help in Decision Making?
Larry A. Allen

10:40 AM
Questions and Answers

10:43 AM
Do Guidelines Distinguish Inpatients from Outpatients?
Sharon A. Hunt

10:53 AM
Questions and Answers

10:56 AM
When Do You Withhold a Recommended Therapy?
Jalal K. Ghali

11:06 AM
Questions and Answers

11:25 AM
When Does Quality of Life Conflict with Otherwise Optimal Therapy?
Ronald M. Witteles

11:40 AM
Case Discussion
Douglas D. Schocken
Eugene S. Chung
John Chin

Learning Objective: Discuss optimal care of selected patients with heart failure based on evidence, guidelines, and reasonable outcomes.